Parkinson's disease is a neurodegenerative movement disorder with a broad spectrum of both motor- and non-motor symptoms. A new top-down model for pathogenesis has recently been suggested, supporting the hypothesis on onset of prodromal non-motor features several years before motor symptoms. Non-motor symptoms have a high prevalence and a substantial effect on quality of life and disease burden. There are limited therapies available for non-motor deficits, although increased focus on pharmacological and non-pharmacological treatments raises quality of life among patients, which is summarised and discussed in this review.